Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cancer Research UK and the National Institute for Health and Care Research are investing over £3 million across the next five years into The University of Oxford’s Experimental Cancer Medicine Centre (ECMC). The investment will enable Oxford to expand its portfolio of precision prevention and early detection cancer trials.

A woman has an IV fitted to a canula in her hand by a nurse wearing blue disposable gloves.

Oxford is part of a network of 17 ECMCs across the UK which work in conjunction with local NHS facilities to deliver clinical trials of promising new treatments.

The new funding will allow Oxford to continue to explore novel, experimental treatments - including immunotherapies - for a wide variety of cancers, as well as trial interventions and improving existing therapies.

Read the full story on the Oxford Cancer website